Sandbox:Haytham: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
{{CMG}}{{AE}}{{HL}} | {{CMG}}{{AE}}{{HL}} | ||
*[[ | ;Durie-Salmon staging system | ||
:* | First published in 1975, the Durie-Salmon staging system <ref name="Salmon">Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. ''Cancer'' 1975;36:842–854. PMID 1182674.</ref> is still in use, but has largely been superseded by the simpler ISS: | ||
::* | * stage 1: all of | ||
** Hb > 10g/dL | |||
** normal calcium | |||
** Skeletal survey: normal or single plasmacytoma or osteoporosis | |||
** Serum [[paraprotein]] level < 5 g/dL if IgG, < 3 g/dL if IgA | |||
** Urinary [[light chain]] excretion < 4 g/24h | |||
* stage 2: fulfilling the criteria of neither 1 nor 3 | |||
* stage 3: one or more of | |||
** Hb < 8.5g/dL | |||
** high calcium > 12mg/dL | |||
** Skeletal survey: 3 or more lytic bone lesions | |||
** Serum paraprotein >7g/dL if IgG, > 5 g/dL if IgA | |||
** Urinary light chain excretion > 12g/24h | |||
{| style="border: 0px; font-size: 90%; margin: 3px; width: 600px" align=center | |||
|valign=top| | |||
|+ | |||
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Stage}} | |||
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Hemoglobin level}} | |||
! style="background: #4479BA; width: 400px;" | {{fontcolor|#FFF|Calcium level}} | |||
! style="background: #4479BA; width: 400px;" | {{fontcolor|#FFF|Skeletal survey}} | |||
! style="background: #4479BA; width: 400px;" | {{fontcolor|#FFF|Serum paraprotein level}} | |||
! style="background: #4479BA; width: 400px;" | {{fontcolor|#FFF|Urinary light chain excretion}} | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | | |||
:Stage 1 | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
*> 10g/dL | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
*8.5-10.2 mg/dL | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
*Normal or single plasmacytoma or osteoporosis | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
*< 5 g/dL if IgG or < 3 g/dL if IgA | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
*< 4 g/24h | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | | |||
:Stage 2 | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
*8.5-10g/dL | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
*10.2-12 mg/dL | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
* fulfilling the criteria of neither 1 nor 3 | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
*5-7 g/dL if IgG or 3-5 g/dL if IgA | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
*4-12 g/24h | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | | |||
:Stage 3 | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
*< 8.5g/dL | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
*> 12mg/dL | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
*3 or more lytic bone lesions | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
*>7g/dL if IgG or > 5 g/dL if IgA | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
*> 12g/24h | |||
|} |
Revision as of 14:46, 19 September 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Haytham Allaham, M.D. [2]
- Durie-Salmon staging system
First published in 1975, the Durie-Salmon staging system [1] is still in use, but has largely been superseded by the simpler ISS:
- stage 1: all of
- Hb > 10g/dL
- normal calcium
- Skeletal survey: normal or single plasmacytoma or osteoporosis
- Serum paraprotein level < 5 g/dL if IgG, < 3 g/dL if IgA
- Urinary light chain excretion < 4 g/24h
- stage 2: fulfilling the criteria of neither 1 nor 3
- stage 3: one or more of
- Hb < 8.5g/dL
- high calcium > 12mg/dL
- Skeletal survey: 3 or more lytic bone lesions
- Serum paraprotein >7g/dL if IgG, > 5 g/dL if IgA
- Urinary light chain excretion > 12g/24h
Stage | Hemoglobin level | Calcium level | Skeletal survey | Serum paraprotein level | Urinary light chain excretion |
---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
- ↑ Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 1975;36:842–854. PMID 1182674.